Arena Pharmaceuticals (Nasdaq: ARNA ) posted its Q3 results, and while there was no ground-breaking news regarding its obesity drug, Belviq, the company did announce a new partnership with South Korean drugmaker Ildong. Arena already has a deal in place with Japanese pharma giant Eisai to market Belviq in major drug markets throughout the Americas.
In the following video, health care analysts Max Macaluso and David Williamson take a close look at the details of this partnership and also discuss the merits of Arena's international strategy.
With this new partnership forging ahead, is Arena still a stock to watch, or is its growth potential evaporating? Before you invest a single dollar, examine this company's opportunities and risks in our brand new premium research report on Arena Pharmaceuticals. Our senior biotech analyst walks investors through essential topics and, since key news can develop quickly, we're also including a full year of updates for those who sign up.Click here now to learn more.